Fisher Asset Management LLC Grows Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Fisher Asset Management LLC increased its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 402.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,468,722 shares of the company's stock after buying an additional 1,977,419 shares during the quarter. Fisher Asset Management LLC owned 0.30% of Dr. Reddy's Laboratories worth $38,981,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of RDY. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company's stock worth $36,000 after buying an additional 137 shares during the last quarter. Van ECK Associates Corp boosted its stake in Dr. Reddy's Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company's stock valued at $64,000 after acquiring an additional 322 shares during the last quarter. Lifestyle Asset Management Inc. grew its position in shares of Dr. Reddy's Laboratories by 3.2% during the 3rd quarter. Lifestyle Asset Management Inc. now owns 13,689 shares of the company's stock valued at $1,088,000 after acquiring an additional 422 shares during the period. Natixis Advisors LLC grew its position in shares of Dr. Reddy's Laboratories by 7.2% during the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company's stock valued at $869,000 after acquiring an additional 735 shares during the period. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Dr. Reddy's Laboratories during the 3rd quarter worth approximately $60,000. 3.85% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have recently commented on RDY shares. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th. StockNews.com cut Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Finally, Barclays cut their target price on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th.

Dr. Reddy's Laboratories Stock Performance

Shares of NYSE:RDY traded up $0.09 during trading on Thursday, hitting $13.01. 431,666 shares of the company were exchanged, compared to its average volume of 1,933,928. Dr. Reddy's Laboratories Limited has a 52-week low of $12.62 and a 52-week high of $16.89. The stock has a 50 day moving average of $14.29 and a 200 day moving average of $14.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company has a market cap of $10.86 billion, a PE ratio of 20.71 and a beta of 0.50.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.